BD Resumes ChloraPrep™ Shipments After Resolving FDA-Related Hold

summarizeSummary

Becton Dickinson announced the resumption of ChloraPrep™ shipments in the U.S. following additional release testing, confirming all tests were acceptable and no patient safety signals were identified.

check_boxKey Events

• Shipments Resumed

  Becton Dickinson has resumed shipments of ChloraPrep™ in the U.S.

• Testing Acceptable

  Additional final release testing for ChloraPrep™ has been completed and found acceptable.

• No Patient Safety Signals

  The company confirmed there have been no patient safety signals related to the products.

• Resolution of Prior Hold

  This action resolves the voluntary ship hold initiated on May 6, 2026, in response to an FDA Warning Letter for the El Paso manufacturing facility.

auto_awesomeAnalysis

This filing provides a positive update on a previously disclosed product hold for ChloraPrep™ and PurPrep™ due to an FDA Warning Letter. The resumption of shipments and confirmation of no patient safety signals remove a regulatory overhang and mitigate potential revenue loss and reputational risk associated with the initial hold.